diagnost tool
buy
price close busi may
global leader diagnost breast imag
surgic product focu women health
slower growth margin pressur move us
sidelin downgrad hold lower pt
start wrong foot year clear disappoint
unclear us reset guid chang fact cynosur appear
near-term catalyst stabil segment convict
achiev goal double-digit growth anytim soon think may figur
believ turnaround cynosur take longer expect
stabil busi might sourc cash point
futur us growth ex-cyno slightli revenu growth slower
like see coupl pressur gm mix shift move sidelin
hope find better entri point also point competit great
compani like ge roch abbott allergan fierc requir superb execut
overcom downgrad hold lower pt
remov one top pick
cyno record surpris goodwil impair charg cynosur
paid net cash cyno rev
q/q miss goal q/q growth abl drive
enough revenu season challeng winter quarter announc two-
third us cyno salesforc new last year mani new last
day impli departur tenur new leader kevin thornal
fulli staf complet expect rep take month
ramp unclear us retain rep place
gm pressur adj gm y/i miss due mix higher
sale lower-margin ou cyno product lower rev higher margin
surgic product declin y/i fxn
guidanc lower revenue guid
report rep upheld adj ep guid
guid adj ep vs
rev rep vs prior
rev rep beat adj ep
match consensu deliv beats/miss
rel model follow breast health skelet health gyn/
surgic off-set shortfal diagnost part due weather
cynosur adj om
model lower rev trim adj ep
vs guid lower rev
y/i lower cynosur revenu estim
lower adj ep penni
lower rev y/i expect lower
growth y/i cynosur lower adj ep y/i
lower adj gm lower
adj gm larg driven product geograph mix shift
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
breast health breast health revenu came fxn
driven strong growth ou partial off-set
flat us busi drove y/i growth intervent breast product
driven growth brevera biopsi affirm prone biopsi system
ou molecular diagnost total ou rev rev grew y/
fxn ex-cyno us sale rev slightli diagnost revenu ex-
blood grew fxn driven fxn growth molecular diagnost
hold buy target price may
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold buy target price may
diagnost tool
hold buy target price may
diagnost tool
